FTC Seeks To Hold Martin Shkreli In Contempt For Allegedly Violating Lifetime Pharmaceutical Industry Ban

What happened: The FTC and seven states filed a motion seeking to hold Martin Shkreli in contempt, alleging he violated a 2022 lifetime pharmaceutical industry ban by trading drug stocks and commenting publicly on drug companies. Key numbers: Daraprim price rose from $17.50 to $750 per tablet. Shkreli traded shares in at least 60 pharmaceutical companies since May 2022. Why it matters: Regulators want him to sell pharmaceutical shares, surrender trading profits plus interest, and face escalating penalties including possible incarceration. No contempt finding has been made yet. Coverage: 10 outlets in 24h

FTC seeks contempt ruling against Shkreli for allegedly violating lifetime pharmaceutical ban.

FTC seeks contempt ruling against Shkreli for allegedly violating lifetime pharmaceutical ban. — impact context not separately stored; see What changed.